Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy Volunteers
- 107 Downloads
To determine the effect of concomitant administration of the antacid Maalox 70® or the histamine H2 receptor antagonist ranitidine on the bioavailability of moxifloxacin.
These were nonblinded, randomised, crossover studies performed in healthy volunteers.
24 healthy males aged 22 to 39 years (study 1; n = 12) and 24 to 43 years (study 2; n = 12) were included in these studies.
In study 1, 12 participants received ranitidine 150mg twice daily during a 3-day pretreatment phase and 1 tablet of ranitidine together with a single 400mg dose of moxifloxacin on the profile day. In study 2, 12 participants received a single 400mg dose of moxifloxacin alone (treatment A), simultaneously with Maalox 70® 10ml (treatment B), or with Maalox 70® 10ml given 4 hours before (treatment C) or 2 hours after (treatment D) the fluoroquinolone. In treatments B, C and D, administration of the antacid (10ml, 1 hour after each meal) was continued for 2 days. Plasma and urine samples were obtained for determination of the pharmacokinetic parameters of moxifloxacin.
Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUC∞) [35.5 versus 34.3 mg/L · h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%]. When moxifloxacin was given simultaneously with Maalox 70®, AUC∞ (14.7 mg/L · h) and Cmax(1.00 mg/L) were reduced by approximately 60%. When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUC∞ values (28.0 and 26.7 versus 34.3 mg/L · h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L). The mean bioavailabilities corrected for the elimination rate constants (λz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70® may interfere with the gastrointestinal recirculation of moxifloxacin.
The bioavailability of moxifloxacin is not affected by concurrent administration of ranitidine. Absorption of moxifloxacin is impaired by concomitant administration of aluminium- and magnesium-containing antacids and administration of these agents should be staggered. An interval of 2 hours before or 4 hours after taking the antacid ensures that the effect of the interaction is not clinically relevant.
KeywordsRanitidine Fluoroquinolones Moxifloxacin Enoxacin Relative Bioavailability
The authors are grateful to Professor A. Dalhoff for contributing the in vitro data used in the modelling studies and for his scientific support during the review of this manuscript. We also express our thanks to Dr S. Wegener for the excellent realisation of the editorial issues as well as to G. Schwarz, P. Hopfe and the medical and laboratory teams for the experimental work in this study. Parts of this paper were presented at the 20th International Congress of Chemotherapy in Sydney in 1997.[38,39]
- 2.Jacobs E, Dalhoff A, Brunner H. Efficacy of BAY 12-8039 in Mycoplasma pneumoniae infected guinea pigs [abstract no. F17]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 102Google Scholar
- 3.Rouse MS, Piper KE, Patel R, et al. In vitro and in vivo activity of BAY 12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice [abstract no. B45]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 29Google Scholar
- 4.Stass H, Kubitza D, Schühly U, et al. Pharmacokinetics, safety, and tolerability of 800 mg BAY 12-8039 administered orally as a single dose [abstract no. P388]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland. Clin Microbiol Infection 1997; 3 Suppl. 2: 87Google Scholar
- 6.Stass H, Schiihly U, Wingender W. Pharmacokinetics, safety, and tolerability of 600 mg BAY 12-8039 administered once daily over 10 days [abstract no. P387]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland. Clin Microbiol Infection 1997; 3 Suppl. 2: 87Google Scholar
- 8.Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982Google Scholar
- 14.Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharm Ther Tox 1991; 29(8): 323–8Google Scholar
- 19.Foster TS, Blouin R. The effect of timing on lomefloxacin bioavailability [abstract]. Pharmacotherapy 1991; 11: 101Google Scholar
- 27.Tuncel T, Bergisadi N. In vitro adsorption of Ciprofloxacin hydrochloride on various antacids. Pharmazie 1992; 47: 304–5Google Scholar
- 29.Zupancic M, Bukovec P. Complexation of magnesium (II) with Ciprofloxacin and norfloxacin. Acta Pharm 1996; 46: 221–8Google Scholar
- 32.Okazaki O, Kurata T, Tachizawa H. Studies on the mechanism of PK interaction of aluminium hydroxide, an antacid, with new quinolones in rats. Xenobiot Metab Dispos 1988; 3: 387–94Google Scholar
- 35.Teng RL, Dogolo LC, Willavize SA, et al. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1994; 39 Suppl. B: 93–7Google Scholar
- 38.Stass H, Ochmann K. Study to evaluate the interaction between BAY 12-8039 and ranitidine [abstract no. 3357]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108Google Scholar
- 39.Stass H, Böttcher M, Horstmann R. Study to evaluate the interaction between BAY 12-8039 and antacids [abstract no. 3358]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108Google Scholar